Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmeris… Read more
Market Cap & Net Worth: Fagron NV (ARSUF)
Fagron NV (OTCGREY:ARSUF) has a market capitalization of $1.47 Billion ($1.47 Billion) as of March 19, 2026. Listed on the OTCGREY stock exchange, this USA-based company holds position #6312 globally and #3566 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fagron NV's stock price $20.03 by its total outstanding shares 73242528 (73.24 Million).
Fagron NV Market Cap History: 2015 to 2025
Fagron NV's market capitalization history from 2015 to 2025. Data shows growth from $532.71 Million to $1.47 Billion (0.00% CAGR).
Fagron NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fagron NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.68x
Fagron NV's market cap is 1.68 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
18.21x
Fagron NV's market cap is 18.21 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $532.71 Million | $427.56 Million | -$202.33 Million | 1.25x | N/A |
| 2016 | $744.25 Million | $421.84 Million | -$20.56 Million | 1.76x | N/A |
| 2017 | $870.94 Million | $433.53 Million | $46.66 Million | 2.01x | 18.67x |
| 2018 | $1.07 Billion | $471.68 Million | $42.49 Million | 2.27x | 25.18x |
| 2019 | $1.44 Billion | $534.70 Million | $41.06 Million | 2.69x | 34.97x |
| 2020 | $1.64 Billion | $555.97 Million | $59.60 Million | 2.95x | 27.51x |
| 2021 | $1.11 Billion | $573.81 Million | $61.00 Million | 1.93x | 18.13x |
| 2022 | $972.18 Million | $683.88 Million | $69.61 Million | 1.42x | 13.97x |
| 2023 | $1.35 Billion | $762.99 Million | $70.55 Million | 1.77x | 19.19x |
| 2024 | $1.47 Billion | $871.96 Million | $80.55 Million | 1.68x | 18.21x |
Competitor Companies of ARSUF by Market Capitalization
Companies near Fagron NV in the global market cap rankings as of March 19, 2026.
Key companies related to Fagron NV by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Fagron NV Historical Marketcap From 2015 to 2025
Between 2015 and today, Fagron NV's market cap moved from $532.71 Million to $ 1.47 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.47 Billion | 0.00% |
| 2024 | $1.47 Billion | +8.39% |
| 2023 | $1.35 Billion | +39.22% |
| 2022 | $972.18 Million | -12.12% |
| 2021 | $1.11 Billion | -32.51% |
| 2020 | $1.64 Billion | +14.17% |
| 2019 | $1.44 Billion | +34.19% |
| 2018 | $1.07 Billion | +22.86% |
| 2017 | $870.94 Million | +17.02% |
| 2016 | $744.25 Million | +39.71% |
| 2015 | $532.71 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Fagron NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.47 Billion USD |
| MoneyControl | $1.47 Billion USD |
| MarketWatch | $1.47 Billion USD |
| marketcap.company | $1.47 Billion USD |
| Reuters | $1.47 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.